Immuno-oncology score predicts response to atezolizumab in TNBC
In the NeoTRIPaPDL1 study, combining information from biomarker analysis at baseline and during treatment was informative on clinical benefit
New drugs for an old target: oral SERDs are active in ER+/HER2– breast cancer
Phase I/II trials also show these compounds have more convenient dosing and are well tolerated in both the early and advanced settings
The paradigm shift led by CDK4/6 inhibitors in breast cancer
The efficacy and overall good tolerability of cyclin-dependent kinase (CDK) 4/6 inhibitors have led to a change in the therapeutic algorithm of HR-positive/HER2-negative advanced breast cancer and established these compounds as the gold standard option for any patient with metastatic disease, except those with visceral crisis.
Longer survival benefit with pembrolizumab plus chemotherapy in TNBC
Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease
Early CDK4/6 inhibitors are not inferior to chemotherapy in HR+/HER2- metastatic breast cancer
Seemingly disappointing survival findings in the final results from the PEARL study are balanced by better quality of life with combination therapy
Phase III data highlight the promise of antibody–drug conjugates in metastatic breast cancer
Significant progression-free survival benefits in pre-treated HER2-positive metastatic disease reported in the DESTINY-BREAST03 and SYD985.002/TULIP trials
Early-stage HER2+ breast cancer may benefit from de-escalated treatment, but biomarkers are still required
Findings from three studies highlight that selecting patients for de-escalated treatment is still challenging
Early and relapsed TNBC is no longer so negative
Research and treatment approaches have come a long way since triple-negative breast cancer was first recognised, but there is still progress to be made, according to Associate Prof. Rebecca Dent
